TICKERNERD
Menu
CAICAIHealthcare · Biotechnology

CAI Stock Forecast: Caris Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$25
+2.10% on the day

The 13 Wall Street analysts covering Caris Life Sciences, Inc. hold a median 12-month price target of $27 — +4.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 2 Sept 2026 — in the lower half.

Market cap
$7.0B
Ticker Nerd rank
34 / 100
Median analyst target
$27
Analysts covering
13
Revenue$263.7M+45.4% y/y
Operating income$26.9M
Net income−$637K
Free cash flow$6.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.0%
1M
+55.1%
YTD
−6.2%
1Y
−31.2%
From 52W high
−31.2%
From 52W low
+74.0%
$15
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Caris Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
78
Revisions
76
Quality
71
Growth
46
Accruals
33
Volatility
29
Size
19
Issuance
19
Momentum
13

Value (78): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (13): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26CAIHigh $36Median $27Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
10 Buy3 Hold0 Sell
Low $22Median $27High $36

The green dot is the last close — the median target sits +4.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Aug 2026BTIGMaintainsBuy$32 → $33
6 Aug 2026Evercore ISI GroupMaintainsOutperform$25 → $26
6 July 2026Evercore ISI GroupMaintainsOutperform$30 → $25
6 July 2026Evercore ISI GroupMaintainsOutperform—
2 July 2026BTIGReiteratesBuy—
2 July 2026BTIGReiteratesBuy$32
2 June 2026Wolfe ResearchAssumesPeer Perform—
8 May 2026BTIGMaintainsBuy—
8 May 2026CitigroupMaintainsBuy—
8 May 2026JP MorganMaintainsOverweight—
13 Apr 2026JefferiesInitiatesBuy—
10 Apr 2026Piper SandlerInitiatesNeutral—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
13 Mar 2026Canaccord GenuityMaintainsHold—
27 Feb 2026BairdMaintainsOutperform—
27 Feb 2026BTIGMaintainsBuy—
27 Feb 2026Evercore ISI GroupMaintainsOutperform—
17 Feb 2026BairdInitiatesOutperform—
22 Dec 2025Canaccord GenuityMaintainsHold—
2 Dec 2025Canaccord GenuityInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CAI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Caris Life Sciences, Inc. returned −31.2% against +21.4% for the S&P 500, dividends included.

CAI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26CAIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.3%
Analysts raising
3
Analysts cutting
3
Fundamentals

Caris Life Sciences, Inc. (CAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.6×

Cheaper than 69% of US stocks

Price / sales
7.1×

Cheaper than 18% of US stocks

Price / book
11.8×

Cheaper than 8% of US stocks

EV / EBITDA
38.3×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
45.4%

Higher than 85% of US stocks

Earnings growth (YoY)
45.4%

Higher than 73% of US stocks

Gross margin
68.1%

Higher than 81% of US stocks

Operating margin
10.2%

Higher than 64% of US stocks

Net margin
10.6%

Higher than 71% of US stocks

Returns & dividend
Return on equity
20.1%

Higher than 81% of US stocks

Return on assets
8.8%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Caris Life Sciences, Inc. (CAI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Caris Life Sciences, Inc. has a market value of $7.0B and an enterprise value of $6.7B.

  • Revenue in the twelve months to 30 June 2026: $989.6M. The latest quarter grew 45.4% year on year.

  • Net income over the same four quarters: $105.1M, a 10.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.36.

  • Free cash flow in the twelve months to 30 June 2026: $124.0M.

  • Caris Life Sciences, Inc. spent $21.5M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 282.6M.

  • Trailing P/E: 2.6×; forward P/E: 65.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Caris Life Sciences, Inc. employs 1,846 people — $536K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

CAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CAICaris Life Sciences, Inc.$7.0B
34
SRRKScholar Rock Holding Corp.$6.8B
33
RYTMRhythm Pharmaceuticals, Inc.$7.3B
89
CGONCG Oncology, Inc.$6.6B
19
SYRESpyre Therapeutics, Inc.$7.5B
46
MIRMMirum Pharmaceuticals, Inc.$6.5B
68
TVTXTravere Therapeutics, Inc.$6.3B
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Caris Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CAI news & analysis

Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer

PRNewsWire · 2 Sept 2026positive

Caris Life Sciences announced that researchers from Caris and the Caris Precision Oncology Alliance will present seven studies at the IASLC 2026 World Conference on Lung Cancer, being held September 12-15, 2026, in Seoul, South Korea. The presentations include two mini oral presentations and a poster tour presentation.

Why it matters — A CAI watcher would care because the company's presence at a major international lung cancer conference highlights its advancing research and visibility in precision oncology.

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice

Proactive Investors · 27 Aug 2026positive

Caris Life Sciences published a study in npj Precision Oncology describing the development and validation of its Caris AI Insights model, an AI tool designed to help doctors select first-line treatment for pancreatic cancer. The model was developed using outcomes from patients treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.

Why it matters — This highlights Caris' continued advancement of AI-powered precision oncology tools, which could broaden the applicability and perceived value of its technology platform for CAI watchers.

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

PRNewsWire · 27 Aug 2026positive

Caris Life Sciences announced the publication of a study in npj Precision Oncology describing the development and validation of Caris AI Insights, an AI-driven approach that uses a molecular signature to predict first-line treatment benefit and optimize therapy selection in pancreatic cancer. The study demonstrates the AI-based tool's performance for personalized care in one of the deadliest malignancies.

Why it matters — CAI watchers would care because this publication highlights the proprietary Caris AI Insights platform, which is exclusive to Caris customers and not achievable through small panels, underscoring the company's differentiated data and AI capabilities in oncology.

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Seeking Alpha · 7 Aug 2026positive

Caris Life Sciences reported another strong quarter, raising its full-year guidance and expanding margins while sustaining positive free cash flow. The company also cited accelerating clinical volume growth and the commercial launch of Caris Detect as evidence of the breadth of its growth drivers.

Why it matters — For CAI watchers, the raised guidance and continued momentum across clinical growth and the Caris Detect launch signal durability in the company's growth drivers.

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Caris Life Sciences, Inc.'s Q2 2026 earnings call. The item presents the company's earnings call coverage for the second quarter of 2026.

Why it matters — A CAI watcher would care because the earnings call transcript provides a primary source of the company's Q2 2026 results and management commentary.

FAQ

Frequently asked questions about CAI stock

What is the CAI stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Caris Life Sciences, Inc. have a median 12-month price target of $27, with estimates ranging from $22 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAI stock a buy right now?

Of the 13 analysts covering Caris Life Sciences, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Caris Life Sciences, Inc. 34 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAI?

As at 2 Sept 2026, Caris Life Sciences, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (78 of 100).

Will CAI stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +4.7% from the last close, and Ticker Nerd's factor model ranks Caris Life Sciences, Inc. 34 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAI stock forecast for 2030?

No analyst covering Caris Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $36 over the next 12 months.

How has CAI stock performed over the past year?

Caris Life Sciences, Inc. returned -31.2% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Caris Life Sciences, Inc. do?

Caris Life Sciences, Inc. Common Stock is the equity of Caris Life Sciences, a precision medicine and diagnostics company focused on molecular profiling and anatomic pathology services.

What is the latest news on CAI?

The most recent item we track (PRNewsWire, 2 Sept 2026): "Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer". Caris Life Sciences announced that researchers from Caris and the Caris Precision Oncology Alliance will present seven studies at the IASLC 2026 World Conference on Lung Cancer, being held September 12-15, 2026, in Seoul, South Korea. The presentations include two mini oral presentations and a poster tour presentation.

Company

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc. Common Stock is the equity of Caris Life Sciences, a precision medicine and diagnostics company focused on molecular profiling and anatomic pathology services. The company uses advanced molecular information and artificial intelligence to help support cancer detection, disease characterization, treatment selection, and recurrence monitoring. Its current portfolio includes tissue-based and blood-based testing solutions, alongside software-driven tools designed to integrate clinical and molecular data for healthcare providers. Caris Life Sciences serves medical practices, laboratories, researchers, and biopharmaceutical partners across the United States and international markets. Headquartered in Irving, Texas, Caris Life Sciences operates at the intersection of biotechnology, data analytics, and clinical diagnostics, making it an important participant in the healthcare technology market.

CEO Dr. David Dean Halbert M.D. · 1,846 employees · United States · https://www.carislifesciences.com